Research ExplorerPublicationsA critical appraisal of systemic treatment options for metas...

A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma

Standard

A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. / Ismail, Salima; Meskawi, Malek; Hansen, Jens; Bianchi, Marco; Tian, Zhe; Latour, Mathieu; Graefen, Markus; Montorsi, Francesco; Trinh, Quoc-Dien; Perrotte, Paul; Karakiewicz, Pierre I; Sun, Maxine.

In: CRIT REV ONCOL HEMAT, Vol. 90, No. 1, 01.04.2014, p. 49-57.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ismail, S, Meskawi, M, Hansen, J, Bianchi, M, Tian, Z, Latour, M, Graefen, M, Montorsi, F, Trinh, Q-D, Perrotte, P, Karakiewicz, PI & Sun, M 2014, 'A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma', CRIT REV ONCOL HEMAT, vol. 90, no. 1, pp. 49-57. https://doi.org/10.1016/j.critrevonc.2013.12.003

APA

Ismail, S., Meskawi, M., Hansen, J., Bianchi, M., Tian, Z., Latour, M., Graefen, M., Montorsi, F., Trinh, Q-D., Perrotte, P., Karakiewicz, P. I., & Sun, M. (2014). A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. CRIT REV ONCOL HEMAT, 90(1), 49-57. https://doi.org/10.1016/j.critrevonc.2013.12.003

Vancouver

Ismail S, Meskawi M, Hansen J, Bianchi M, Tian Z, Latour M et al. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. CRIT REV ONCOL HEMAT. 2014 Apr 1;90(1):49-57. https://doi.org/10.1016/j.critrevonc.2013.12.003

Bibtex

@article{91b0bee996ad43c5bf38dd7f38b6e3ae,
title = "A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma",
abstract = "Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.",
keywords = "Antineoplastic Agents, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Molecular Targeted Therapy",
author = "Salima Ismail and Malek Meskawi and Jens Hansen and Marco Bianchi and Zhe Tian and Mathieu Latour and Markus Graefen and Francesco Montorsi and Quoc-Dien Trinh and Paul Perrotte and Karakiewicz, {Pierre I} and Maxine Sun",
note = "Copyright {\textcopyright} 2013 Elsevier Ireland Ltd. All rights reserved.",
year = "2014",
month = apr,
day = "1",
doi = "10.1016/j.critrevonc.2013.12.003",
language = "English",
volume = "90",
pages = "49--57",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma

AU - Ismail, Salima

AU - Meskawi, Malek

AU - Hansen, Jens

AU - Bianchi, Marco

AU - Tian, Zhe

AU - Latour, Mathieu

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Trinh, Quoc-Dien

AU - Perrotte, Paul

AU - Karakiewicz, Pierre I

AU - Sun, Maxine

N1 - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.

AB - Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.

KW - Antineoplastic Agents

KW - Carcinoma, Renal Cell

KW - Humans

KW - Kidney Neoplasms

KW - Molecular Targeted Therapy

U2 - 10.1016/j.critrevonc.2013.12.003

DO - 10.1016/j.critrevonc.2013.12.003

M3 - SCORING: Journal article

C2 - 24411587

VL - 90

SP - 49

EP - 57

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

IS - 1

ER -